Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1592120rdf:typepubmed:Citationlld:pubmed
pubmed-article:1592120lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1592120lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:1592120lifeskim:mentionsumls-concept:C0021753lld:lifeskim
pubmed-article:1592120lifeskim:mentionsumls-concept:C0224522lld:lifeskim
pubmed-article:1592120lifeskim:mentionsumls-concept:C0599781lld:lifeskim
pubmed-article:1592120lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:1592120lifeskim:mentionsumls-concept:C0442821lld:lifeskim
pubmed-article:1592120lifeskim:mentionsumls-concept:C1363844lld:lifeskim
pubmed-article:1592120pubmed:issue1lld:pubmed
pubmed-article:1592120pubmed:dateCreated1992-6-30lld:pubmed
pubmed-article:1592120pubmed:abstractTextHigher basal 2-deoxy-D-glucose uptake in rheumatoid synovial cells than in non-rheumatoid synovial cells, was found to be associated with an increased interleukin-1 beta (IL-1 beta) secretion (respectively 850 +/- 238 vs. 8.3 +/- 2.4 pg/24 h/10(5) cells, mean +/- S.E.M.). When exogenous human recombinant IL-1 beta was added to cultures, a marked stimulation of 2-deoxy-D-glucose uptake was performed by both human synovial cultured cells, in a time-dependent and dose-dependent manner (IL-1 beta 0-100 ng/ml). In non-rheumatoid synoviocytes, stimulation occurred 1-3 h following the addition of 1 ng/ml interleukin-1 beta and increased up to 24 hours (respectively +150% and +261.4% after 6 and 24 hours association time). Rheumatoid synovial cells were less sensitive to 1 ng/ml IL-1 beta (respectively +80% and +146.4%). IL-1 beta increased significantly the Vmax for 2-deoxy-D-glucose uptake by synovial cells, with no change in the Km. This effect was protein synthesis-dependent, and not secondary to prostaglandin E2 synthesis or cell growth. IL-1 beta possesses an important effect on glucose homeostasis in synovial cells, which could be indirect and/or regulated by the presence of natural inhibitors.lld:pubmed
pubmed-article:1592120pubmed:languageenglld:pubmed
pubmed-article:1592120pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1592120pubmed:citationSubsetIMlld:pubmed
pubmed-article:1592120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1592120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1592120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1592120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1592120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1592120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1592120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1592120pubmed:statusMEDLINElld:pubmed
pubmed-article:1592120pubmed:monthMaylld:pubmed
pubmed-article:1592120pubmed:issn0014-5793lld:pubmed
pubmed-article:1592120pubmed:authorpubmed-author:MoattiNNlld:pubmed
pubmed-article:1592120pubmed:authorpubmed-author:AusselCClld:pubmed
pubmed-article:1592120pubmed:authorpubmed-author:EkindjianO...lld:pubmed
pubmed-article:1592120pubmed:authorpubmed-author:CynoberLLlld:pubmed
pubmed-article:1592120pubmed:authorpubmed-author:HernvannAAlld:pubmed
pubmed-article:1592120pubmed:issnTypePrintlld:pubmed
pubmed-article:1592120pubmed:day25lld:pubmed
pubmed-article:1592120pubmed:volume303lld:pubmed
pubmed-article:1592120pubmed:ownerNLMlld:pubmed
pubmed-article:1592120pubmed:authorsCompleteYlld:pubmed
pubmed-article:1592120pubmed:pagination77-80lld:pubmed
pubmed-article:1592120pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:meshHeadingpubmed-meshheading:1592120-...lld:pubmed
pubmed-article:1592120pubmed:year1992lld:pubmed
pubmed-article:1592120pubmed:articleTitleIL-1 beta, a strong mediator for glucose uptake by rheumatoid and non-rheumatoid cultured human synoviocytes.lld:pubmed
pubmed-article:1592120pubmed:affiliationBiochimie Cellulaire de l'Inflammation, Université Paris XI, Chatenay-Malabry, France.lld:pubmed
pubmed-article:1592120pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1592120pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed